These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 31983170

  • 1. Predicting Response to Neoadjuvant Chemotherapy Using 18F FDG PET-CT in Patients with Locally Advanced Breast Cancer.
    Hulikal N, Gajjala SR, Kalawat T, Kadiyala S, Kottu R.
    Asian Pac J Cancer Prev; 2020 Jan 01; 21(1):93-98. PubMed ID: 31983170
    [Abstract] [Full Text] [Related]

  • 2. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, Mehta SN.
    Eur Radiol; 2009 Jun 01; 19(6):1347-57. PubMed ID: 19214522
    [Abstract] [Full Text] [Related]

  • 3. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L, Cervino AR, Michieletto S, Saibene T, Orvieto E, Bozza F, Ghiotto C.
    Q J Nucl Med Mol Imaging; 2017 Jun 01; 61(2):205-215. PubMed ID: 25501326
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer.
    Chung YS, Kim HS, Lee JY, Kang WJ, Nam EJ, Kim S, Kim SW, Kim YT.
    Cancer Res Treat; 2020 Oct 01; 52(4):1211-1218. PubMed ID: 32599990
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, Skaltsa K, Domènech B, Lomeña F, Pons F.
    Q J Nucl Med Mol Imaging; 2012 Jun 01; 56(3):291-8. PubMed ID: 22695339
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
    Cheng X, Li Y, Liu B, Xu Z, Bao L, Wang J.
    Acta Radiol; 2012 Jul 01; 53(6):615-27. PubMed ID: 22734080
    [Abstract] [Full Text] [Related]

  • 18. Intratumoral heterogeneity in 18F-FDG PET/CT by textural analysis in breast cancer as a predictive and prognostic subrogate.
    Molina-García D, García-Vicente AM, Pérez-Beteta J, Amo-Salas M, Martínez-González A, Tello-Galán MJ, Soriano-Castrejón Á, Pérez-García VM.
    Ann Nucl Med; 2018 Jul 01; 32(6):379-388. PubMed ID: 29869770
    [Abstract] [Full Text] [Related]

  • 19. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J, Wang Y, Mo M, Bao X, Zhang Y, Liu G, Zhang J, Geng D.
    Oncotarget; 2015 Oct 06; 6(30):29388-95. PubMed ID: 26336821
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.